News

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

Celularity's clinical trial of CYNK-001 for relapsed and refractory AML showed excellent tolerability, significant graft-versus-leukemia effects, and potential for flexible therapeutic development.

The biosimilars were equivalent with the biologic regarding both ACR20 response achievement and change of Health Assessment Questionnaire-Disability Index (HAQ-DI) scores at month 6.

An analysis of 2 population-based cohorts suggests coronary artery calcium scores added to traditional risk-based models showed better discrimination than polygenic risk scores for CHD risk prediction.

Late-breaking data validates the FDA clearance of Cytovale's IntelliSep test, demonstrating its potential to aid in the early detection of sepsis in US emergency departments, with the aim of improving patient outcomes.

At the 12-month mark, opioid discontinuation occurred in 29% of patients in the intervention cohort compared with only 7% in the usual care group.

An analysis of over 300,000 Medicare admissions showed no clinically important differences regarding mortality, readmission, length of stay, and healthcare spending between the two groups.

Pooling data from half a dozen major population-based cohort studies, a Johns Hopkins-led team provides new insight into the risk of cognitive decline following myocardial infarction among US adults.

An analysis of data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program provides an overview of changing rates of access and utilization of metabolic and bariatric surgery among US youths.

The rate of sleep apnea is greater in patients with bipolar disorder and depression.

New data indicates that psoriasis patients who are naïve to biological therapies may benefit from early intervention with secukinumab, though further research is needed.

The results show 26.3% of patients in the daily cannabis use only group endorsed 2 or more items on the symptom checklist, consistent with DSM-5 SUD, compared to 30.2% of the other drug use group and 51.8% of the daily cannabis and other drug use group.

This research from Japan on the shifting preferences for individuals with psoriasis in the pre and post-pandemic era may indicate the effects of such events on treatment options.

Both gastrointestinal surgery and appendectomies were not associated with any increased risk of psoriasis development in a national cohort.

A prospective cohort analysis of Denmark residents suggests correlation between cannabis overuse and risk of psychiatric conditions.

Late-breaking data from ATS 2023 show new positive evidence of the innovative in-vitro diagnostic tool IntelliSep test that measures the viscoelastic properties of leukocytes, showing promising results for rapid sepsis diagnosis in EDs.

Clinical trial data suggest overweight and obese patients with atrial fibrillation who lose weight prior to a catheter ablation procedure experience better clinical outcomes.

This study highlighted the strong effects of environmental factors on eczema, especially given the higher prevalence of the skin condition in industrialized countries.

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

Scott Solomon, MD, of Brigham and Women's Hospital, discusses how baseline patient characteristics inform what cardiologists might learn from the FINEARTS-HF trial, which he presented at Heart Failure 2023.

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

Janssen's efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce.

Differences in Lp(a) level distribution across the diverse US Hispanic or Latino population may have important implications for its use in ASCVD risk assessment.

New prospective data show more adult patients achieved clinical response with ketamine than the historic standard ECT over a 6-month regimen.

There were several risk factors identified, including abortion, hospitalization, past surgical procedure, dental extraction, delivery in hospital, injection in hospitals, and household contact with jaundice.

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

New research has led to the development of an algorithm designed to help improve detection of allergic reactions to antibiotics, given that antibiotics are among the most common medication adverse event causes.

Results from the analysis suggest participants treated for previously diagnosed obstructive sleep apnea experience a significantly higher risk of having RPD coexistent with AMD.

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

In today’s episode, we explore how the lived experience of someone with rheumatoid arthritis can systematically be documented via the use of patient-reported outcome measures.